254 related articles for article (PubMed ID: 23018438)
1. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.
Martínez E; D'Albuquerque PM; Llibre JM; Gutierrez F; Podzamczer D; Antela A; Berenguer J; Domingo P; Moreno X; Perez I; Pich J; Gatell JM;
AIDS; 2012 Nov; 26(18):2315-26. PubMed ID: 23018438
[TBL] [Abstract][Full Text] [Related]
2. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM;
AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917
[TBL] [Abstract][Full Text] [Related]
3. Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study.
Masiá M; Martínez E; Padilla S; Gatell JM; Gutiérrez F
J Antimicrob Chemother; 2013 Feb; 68(2):409-13. PubMed ID: 23075691
[TBL] [Abstract][Full Text] [Related]
4. LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy.
Saumoy M; Sánchez-Quesada JL; Martínez E; Llibre JM; Ribera E; Knobel H; Gatell JM; Clotet B; Curran A; Curto J; Masó M; Ordoñez-Llanos J; Podzamczer D
Atherosclerosis; 2012 Nov; 225(1):200-7. PubMed ID: 23017355
[TBL] [Abstract][Full Text] [Related]
5. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
[TBL] [Abstract][Full Text] [Related]
6. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients.
Rosenson RS
Obesity (Silver Spring); 2009 Mar; 17(3):504-9. PubMed ID: 19023279
[TBL] [Abstract][Full Text] [Related]
7. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy.
Curran A; Martinez E; Saumoy M; del Rio L; Crespo M; Larrousse M; Podzamczer D; Burgos J; Lonca M; Domingo P; Gatell JM; Ribera E
AIDS; 2012 Feb; 26(4):475-81. PubMed ID: 22112606
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress and inflammatory markers in relation to circulating levels of adiponectin.
Gustafsson S; Lind L; Söderberg S; Zilmer M; Hulthe J; Ingelsson E
Obesity (Silver Spring); 2013 Jul; 21(7):1467-73. PubMed ID: 23585283
[TBL] [Abstract][Full Text] [Related]
9. Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults.
Samaras K; Richardson R; Carr A
AIDS; 2010 Jul; 24(11):1727-31. PubMed ID: 20588105
[TBL] [Abstract][Full Text] [Related]
10. Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors.
Petit JM; Duong M; Masson D; Buisson M; Duvillard L; Bour JB; Brindisi MC; Galland F; Guiguet M; Gambert P; Portier H; Vergès B
Eur J Clin Invest; 2004 Aug; 34(8):569-75. PubMed ID: 15305892
[TBL] [Abstract][Full Text] [Related]
11. Adiponectin and E-selectin concentrations in relation to inflammation in obese type 2 diabetic patients with coronary heart disease(s).
El-Mesallamy HO; Hamdy NM; Salman TM; Mahmoud S
Minerva Endocrinol; 2011 Sep; 36(3):163-70. PubMed ID: 22019747
[TBL] [Abstract][Full Text] [Related]
12. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
13. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial.
Depalma RG; Hayes VW; Chow BK; Shamayeva G; May PE; Zacharski LR
J Vasc Surg; 2010 Jun; 51(6):1498-503. PubMed ID: 20304584
[TBL] [Abstract][Full Text] [Related]
14. Impact of antiretroviral therapy interruption on plasma biomarkers of cardiovascular risk and lipids: 144-week final data from the STOPAR study.
Olmo M; Saumoy M; Alonso-Villaverde C; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Curto J; Domingo P; Oteo JA; Vila A; Podzamczer D
HIV Med; 2012 Sep; 13(8):488-98. PubMed ID: 22416676
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
16. A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity.
Moyle GJ; Andrade-Villanueva J; Girard PM; Antinori A; Salvato P; Bogner JR; Hay P; Santos J; Astier L; Pans M; Balogh A; Biguenet S;
Antivir Ther; 2012; 17(4):689-700. PubMed ID: 22388634
[TBL] [Abstract][Full Text] [Related]
17. E-selectin and TFPI are associated with carotid intima-media thickness in stable IHD patients: the baseline findings of the MIAMI study.
Porta B; Baldassarre D; Camera M; Amato M; Arquati M; Brusoni B; Fiorentini C; Montorsi P; Romano S; Tremoli E; Cortellaro M;
Nutr Metab Cardiovasc Dis; 2008 May; 18(4):320-8. PubMed ID: 17889518
[TBL] [Abstract][Full Text] [Related]
18. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
Behrens G; Maserati R; Rieger A; Domingo P; Abel F; Wang H; Pearce G
Antivir Ther; 2012; 17(6):1011-20. PubMed ID: 22910324
[TBL] [Abstract][Full Text] [Related]
19. Changes in biomarkers in HIV-1-infected treatment-naive patients treated with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for 96 weeks: the CASTLE biomarker substudy.
Moyle G; Hardy H; Uy J; Ray N; Jimenez-Exposito MJ; McGrath D; DeJesus E
Antivir Ther; 2014; 19(7):693-9. PubMed ID: 24739445
[TBL] [Abstract][Full Text] [Related]
20. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy.
Silva EF; Charreau I; Gourmel B; Mourah S; Kalidi I; Guillon B; De Castro N; Caron F; Braun J; Molina JM;
J Infect Dis; 2013 Sep; 208(6):892-7. PubMed ID: 23801606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
